Summary
Clinical characteristics.
Cockayne syndrome (referred to as CS in this GeneReview) spans a continuous phenotypic spectrum that includes:
CS type I, the "classic" or "moderate" form;
CS type II, a more severe form with symptoms present at birth; this form overlaps with cerebrooculofacioskeletal (COFS) syndrome;
CS type III, a milder and later-onset form;
COFS syndrome, a fetal form of CS.
CS type I is characterized by normal prenatal growth with the onset of growth and developmental abnormalities in the first two years. By the time the disease has become fully manifest, height, weight, and head circumference are far below the fifth percentile. Progressive impairment of vision, hearing, and central and peripheral nervous system function leads to severe disability; death typically occurs in the first or second decade.
CS type II is characterized by growth failure at birth, with little or no postnatal neurologic development. Congenital cataracts or other structural anomalies of the eye may be present. Affected children have early postnatal contractures of the spine (kyphosis, scoliosis) and joints. Death usually occurs by age five years.
CS type III is a phenotype in which major clinical features associated with CS only become apparent after age two years; growth and/or cognition exceeds the expectations for CS type I.
COFS syndrome is characterized by very severe prenatal developmental anomalies (arthrogryposis and microphthalmia).
Management.
Treatment of manifestations: Feeding gastrostomy tube placement as needed; individualized educational programs for developmental delay; medications for tremor and spasticity as needed; physical therapy to prevent contractures; use of sunglasses for lens/retina protection; treatment of cataracts, and other ophthalmologic complications, hearing loss, hypertension, and gastroesophageal reflux as in the general population. Aggressive dental care to minimize dental caries; use of sunscreens and limitation of sun exposure for cutaneous photosensitivity.
Surveillance: Biannual assessment of diet, nervous system, and ophthalmologic status. Yearly assessment for complications such as hearing loss, hepatic or renal dysfunction, and hypertension.
Agents/circumstances to avoid: Excessive sun exposure and use of metronidazole. Extra vigilance is needed for opioid and sedative use. Use of growth hormone treatment is not recommended in those with CS.
Genetic counseling.
Cockayne syndrome is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible if the ERCC6 or ERCC8 pathogenic variants in the family are known.
Diagnosis
Cockayne syndrome (CS) is characterized by growth failure and multisystemic involvement, with a variable age of onset and rate of progression. To facilitate clinical recognition and follow up, the phenotypic spectrum of CS can be divided into different clinical presentations. Note, however, that among all individuals with CS there is a continuous spectrum of clinical severities without clear thresholds and that intermediate phenotypes may arise:
Cockayne syndrome type I, "classic" CS, in which the major features of the disease become apparent by age one to two years
Cockayne syndrome type II, a more severe form with abnormalities recognized at birth or in the early neonatal period
Cockayne syndrome type III, milder/later-onset forms in which major features only become apparent after age two years
Cerebrooculofacioskeletal (COFS) syndrome, very severe fetal
phenotype with arthrogryposis, prenatal growth failure, prenatal microcephaly,
congenital cataracts or microphthalmia
Formal clinical diagnostic criteria originally proposed for CS type I [Nance & Berry 1992] have been revised and extended in more recent publications [Natale 2011, Laugel 2013]. Because of the progressive nature of CS, the clinical diagnosis becomes more certain as additional signs and symptoms gradually manifest over time.
Suggestive Findings
Cockayne syndrome should be suspected in individuals with the following findings.
Major criteria
Minor criteria
Cutaneous photosensitivity
Demyelinating peripheral neuropathy diagnosed by nerve conduction testing
Pigmentary retinopathy and/or cataracts
Sensorineural hearing loss
Dental anomalies including dental caries, enamel hypoplasia, and anomalies of tooth number and tooth size and shape
A characteristic physical appearance of "cachectic dwarfism" with sunken eyes
CS type I (classic) is suspected:
In an older child when both major criteria are present and three minor criteria are present;
In an infant or toddler when both major criteria are present, especially if there is increased cutaneous photosensitivity.
CS type II (severe) is suspected:
In infants with growth failure at birth and little postnatal increase in height, weight, or head circumference;
When there is little or no postnatal neurologic development;
CS Type III (mild) is suspected:
In children or teenagers with short stature, mild neurologic impairment, and progressive ataxia;
Especially but not exclusively when there is cutaneous photosensitivity.
COFS syndrome is suspected when prenatal growth failure and prenatal microcephaly are associated with arthrogryposis and congenital cataracts as well as other structural defects of the eye (microphthalmos, microcornea, iris hypoplasia).
Establishing the Diagnosis
The diagnosis of Cockayne syndrome is established in a proband by identification of biallelic pathogenic variants in ERCC6 or ERCC8 on molecular genetic testing (see Table 1).
Molecular genetic testing approaches can include a combination of gene-targeted testing (multigene panel) and comprehensive
genomic testing (chromosomal microarray analysis, exome sequencing, exome array, genome sequencing) depending on the phenotype.
Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing does not. Because the phenotype of Cockayne syndrome is broad, individuals with the distinctive findings described in Suggestive Findings are likely to be diagnosed using gene-targeted testing (see Option 1), whereas those in whom the diagnosis of Cockayne syndrome has not been considered are more likely to be diagnosed using genomic testing (see Option 2).
Option 1
When the phenotypic findings suggest the diagnosis of Cockayne syndrome the recommended molecular genetic testing approach is to use a multigene panel.
A multigene panel that includes ERCC6, ERCC8, and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see Table 1).
For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
Option 2
When the diagnosis of Cockayne syndrome is not considered because an individual has atypical phenotypic features, comprehensive genomic testing (which does not require the clinician to determine which gene[s] are likely involved) is the best option. Exome sequencing is most commonly used; genome sequencing is also possible.
If exome sequencing is not diagnostic, exome array (when clinically available) may be considered to detect (multi)exon deletions or duplications that cannot be detected by sequence analysis.
For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.
Table 1.
Molecular Genetic Testing Used in Cockayne Syndrome
View in own window
| Gene 1, 2 | Proportion of Cockayne Syndrome Attributed to Pathogenic Variants in Gene | Proportion of Pathogenic Variants 3 Detectable by Method |
|---|
| Sequence analysis 4 | Gene-targeted deletion/duplication analysis 5 |
|---|
|
ERCC6
| ~65% | 90%6 | 10% 6 |
|
ERCC8
| ~35% | 88% 6 | 12% 6 |
- 1.
Genes are listed in alphabetic order.
- 2.
- 3.
- 4.
- 5.
Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.
- 6.
DNA Repair Assay
If the diagnosis of Cockayne syndrome is strongly suspected, but the molecular genetic testing does not identify pathogenic variants in one of the associated genes, an assay of the cellular phenotype can be considered.
Assays of DNA repair are performed on skin fibroblasts. The most consistent findings in CS fibroblasts are marked sensitivity to UV radiation and deficient recovery of RNA synthesis following UV damage (i.e., impaired repair of actively transcribed genes, or "transcription-coupled repair") [Nakazawa et al 2010].
Clinical Characteristics
Clinical Description
Before the molecular genetics of Cockayne syndrome was understood, it was thought to have a single, discrete phenotype: classic Cockayne syndrome. It is now recognized that Cockayne syndrome spans a continuous phenotypic spectrum without clear thresholds, and includes the following [Nance & Berry 1992]:
CS type I, the "classic" form
CS type II, a more severe form with symptoms present at birth (overlapping with cerebrooculofacioskeletal syndrome [COFS])
CS type III, a milder form
Cerebrooculofacioskeletal (COFS) syndrome, the most severe end of the phenotypic spectrum of CS with findings identifiable during fetal life
CS Type I
Presentation. Prenatal growth is typically normal. Birth length, weight, and head circumference are normal. Within the first two years, however, growth and development fall below normal. By the time the disease has become fully manifest, height, weight, and head circumference are far below the fifth percentile.
Progression. Progressive impairment of vision, hearing, and central and peripheral nervous system function leads to severe disability. Brain MRI reveals white matter dysmyelination and progressive cerebral and cerebellar atrophy. Photosensitivity is variable, but individuals are not predisposed to skin cancers.
Additional clinical abnormalities occurring in 10% or more of individuals include the following:
Neurologic. Increased tone/spasticity, hyper- or hyporeflexia, stooped standing posture, abnormal gait or inability to walk, ataxia, incontinence, tremor, abnormal or absent speech, seizures, weak cry / poor feeding (as an infant), muscle atrophy, and behavior abnormality
Ophthalmologic. Enophthalmos, pigmentary retinopathy (60%-100%), abnormal electroretinogram, cataracts of various types (15%-36%), optic atrophy, miotic pupils, farsightedness, decreased or absent tears, strabismus, nystagmus, photophobia, narrowed retinal arterioles
Hearing. Sensorineural hearing loss
Dental. Absent or hypoplastic teeth, enamel hypoplasia, delayed eruption of deciduous teeth, and malocclusion. Enamel anomalies frequently lead to severe dental caries [
Bloch-Zupan et al 2013].
Skeletal. Radiographic findings of thickened calvarium (due to microcephaly), sclerotic epiphyses, vertebral and pelvic abnormalities
Endocrine. Undescended testes, delayed/absent sexual maturation, diabetes
Gastrointestinal. Elevated liver function tests, enlargement of liver or spleen, gastroesophageal reflux
Death typically occurs in the first or second decade. The mean age of death is 16 years, although survival into the third decade has been reported [Natale 2011].
CS Type II
Children with severe CS have evidence of growth failure at birth, with little or no postnatal neurologic development. Congenital cataracts or other structural anomalies of the eye are present in 30%. Affected individuals may have some contractures of the spine (kyphosis, scoliosis) and joints in neonatal or early postnatal life. Affected children typically die by age five years [Natale 2011]. CS type II partly overlaps with cerebrooculofacioskeletal (COFS) syndrome.
CS Type III
DNA sequencing has confirmed the diagnosis of CS type III in some individuals who have clinical features associated with CS but whose growth and/or cognition exceeds the expectations for CS type I [Natale 2011, Baez et al 2013]. Major features only become apparent after age two years.
COFS Syndrome
COFS syndrome is the most severe subtype of the CS spectrum and can be identified during fetal life. Similarly to individuals with CS type II, individuals with COFS syndrome present with severe prenatal growth failure, severe developmental delay / intellectual disability from birth, axial hypotonia, peripheral hypertonia, and neonatal feeding difficulties. COFS syndrome is additionally defined by the presence of arthrogryposis and usually the combination of extreme congenital microcephaly and congenital cataracts [Laugel et al 2008].
Neuropathology. In all forms of Cockayne syndrome, a characteristic "tigroid" pattern of demyelination in the subcortical white matter of the brain and multifocal calcium deposition, with relative preservation of neurons and without senile plaques, amyloid, ubiquitin, or tau deposition, has been observed together with arteriosclerosis [Weidenheim et al 2009, Hayashi et al 2012].
Nomenclature
The term cerebrooculofacioskeletal (COFS) syndrome and its former synonym, Pena-Shokeir syndrome type II, have been used to refer to a heterogeneous group of disorders characterized by congenital neurogenic arthrogryposis (multiple joint contractures), microcephaly, microphthalmia, and cataracts. The original cases of COFS syndrome, described by Pena & Shokeir [1974] among native Canadian families from Manitoba, have since been shown to be homozygous for a pathogenic variant in ERCC6. COFS syndrome is now regarded as an allelic and prenatal form of CS, partly overlapping with CS type II and including the most severe cases of the CS phenotypic spectrum [Laugel et al 2008].
Prevalence
The minimum incidence of CS has been estimated at 2.7 per million births in western Europe; the disease is probably underdiagnosed [Kleijer et al 2008].
Differential Diagnosis
The differential diagnosis of Cockayne syndrome (CS) depends on the presenting features of the particular individual (see Table 3). Abnormalities that suggest alternative diagnoses include: congenital anomalies of the face, limbs, heart, or viscera; recurrent infections (other than otitis media or respiratory infections); metabolic or neurologic crises; hematologic abnormality (e.g., anemia, leukopenia); and cancer of any kind.
Growth failure is seen in chromosome disorders and endocrine, metabolic, or gastrointestinal disorders, including malnutrition.
Table 3.
Disorders to Consider in the Differential Diagnosis of Cockayne Syndrome
View in own window
- 1.
Most leukodystrophies are not associated with growth failure, with the possible exception of the connatal form of Pelizaeus-Merzbacher disease.
- 2.
- 3.
ATR, CENPJ, CEP152, CEP63, DNA2, NIN, NSMCE2, RBBP8, TRAIP
- 4.
DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC
- 5.
Warburg micro syndrome (OMIM PS600118), associated with biallelic pathogenic variants in RAB18,RAB3GAP1, RAB3GAP2, or TBC1D20 and presenting with microcephaly, microcornea, and cataracts, may resemble CS type II / COFS syndrome at birth. However; Warburg micro syndrome is not associated with rapidly progressive neurodegeneration and has normal DNA nucleotide excision repair [Graham et al 2004].
Management
Evaluations Following Initial Diagnosis
To establish the extent of disease and needs in an individual diagnosed with Cockayne syndrome (CS), the evaluations summarized in Table 4 (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
Recommended Evaluations Following Initial Diagnosis in Individuals with Cockayne Syndrome
View in own window
System/
Concern | Evaluation | Comment |
|---|
|
Growth
|
| |
|
Development
| Developmental assessment |
To incl motor, adaptive, cognitive & speech/language eval Eval for early intervention / special education
|
|
Neurologic
|
| |
|
Eyes
| Ophthalmologic eval | Possibly incl electroretinogram. |
|
Hearing
| Audiologic eval | Incl audiogram. |
|
Skin
| Dermatologic eval | |
|
Teeth
| Dental eval | |
|
Skeletal
| Radiographs to document skeletal dysplasia if suggestive clinical signs | |
|
Kidneys
| Laboratory eval of renal function | |
|
Liver
| Laboratory eval of liver function | |
|
Other
| Consultation w/clinical geneticist &/or genetic counselor | |
Treatment of Manifestations
Table 5.
Treatment of Manifestations in Individuals with Cockayne Syndrome
View in own window
| Manifestation/Concern | Treatment |
|---|
|
Poor growth
| Feeding gastrostomy tube placement as needed. Note: Avoid rapid ↑ in volume of feeds. |
Developmental delay /
Intellectual disability
| See Developmental Delay / Intellectual Disability Management Issues. |
|
Tremor - spasticity
|
|
|
Abnormal vision and/or cataracts
|
|
|
Hearing loss
|
|
|
Dental caries
| Aggressive dental care to minimize caries |
|
Cutaneous photosensitivity
| Use of sunscreens; limitation of sun exposure |
|
Hypertension
| Amlodipine, ACE inhibitor |
|
Gastroesophageal reflux
| Proton pump inhibitor |
Developmental Delay / Intellectual Disability Management Issues
The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country.
Ages 0-3 years. Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy as well as infant mental health services, special educators, and sensory impairment specialists. In the US, early intervention is a federally funded program available in all states that provides in-home services to target individual therapy needs.
Ages 3-5 years. In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed for those who qualify based on established motor, language, social, or cognitive delay. The early intervention program typically assists with this transition. Developmental preschool is center based; for children too medically unstable to attend, home-based services are provided.
All ages. Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies (US) and to support parents in maximizing quality of life. Some issues to consider:
IEP services:
An IEP provides specially designed instruction and related services to children who qualify.
IEP services will be reviewed annually to determine if any changes are needed.
Special education law requires that children participating in an IEP be in the least restricted environment feasible at school and included in general education as much as possible, when and where appropriate.
Vision and hearing consultants should be a part of the child’s IEP team to support access to academic material.
PT, OT and speech services will be provided in the IEP to the extent that the need affects the child's access to academic material. Beyond that, private supportive therapies based on the affected individual's needs may be considered. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.
As a child enters teen years, a transition plan should be discussed and incorporated in the IEP. For those receiving IEP services, the public school district is required to provide services until age 21.
A 504 plan (Section 504: a US federal statute that prohibits discrimination based on disability) can be considered for those who require accommodations or modifications such as front-of-class seating, assistive technology devices, classroom scribes, extra time between classes, modified assignments, and enlarged text.
Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a US public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.
Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.
Motor Dysfunction
Gross motor dysfunction
Physical therapy is recommended to maximize mobility and to reduce the risk for later-onset orthopedic complications (e.g., contractures, scoliosis, hip dislocation).
Consider use of durable medical equipment and positioning devices as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, adaptive strollers).
For muscle tone abnormalities including hypertonia or dystonia, consider involving appropriate specialists to aid in management of baclofen, tizanidine, Botox®, anti-parkinsonian medications, or orthopedic procedures.
Fine motor dysfunction. Occupational therapy is recommended for difficulty with fine motor skills that affect adaptive function such as feeding, grooming, dressing, and writing.
Oral motor dysfunction should be reassessed at each visit and clinical feeding evaluations and/or radiographic swallowing studies should be obtained for choking/gagging during feeds, poor weight gain, frequent respiratory illnesses or feeding refusal that is not otherwise explained. Assuming that the individual is safe to eat by mouth, feeding therapy (typically from an occupational or speech therapist) is recommended to help improve coordination or sensory-related feeding issues. Feeds can be thickened or chilled for safety. When feeding dysfunction is severe, an NG-tube or G-tube may be necessary.
Communication issues. Consider evaluation for alternative means of communication (e.g., Augmentative and Alternative Communication [AAC]) for individuals who have expressive language difficulties. An AAC evaluation can be completed by a speech language pathologist who has expertise in the area. The evaluation will consider cognitive abilities and sensory impairments to determine the most appropriate form of communication. AAC devices can range from low-tech, such as picture exchange communication, to high-tech, such as voice-generating devices. Contrary to popular belief, AAC devices do not hinder verbal development of speech, and in many cases can improve it.
Social/Behavioral Concerns
Children may qualify for and benefit from interventions used in treatment of autism spectrum disorder, including applied behavior analysis (ABA). ABA therapy is targeted to the individual child's behavioral, social, and adaptive strengths and weaknesses and is typically performed one on one with a board-certified behavior analyst.
Consultation with a developmental pediatrician may be helpful in guiding parents through appropriate behavior management strategies or providing prescription medications.
Surveillance
Yearly reassessment for known potential complications (e.g., hypertension, renal or hepatic dysfunction, declining vision and hearing) is appropriate [Laugel 2013, Wilson et al 2015]. See Table 6 for specific recommendations.
Table 6.
Recommended Surveillance for Individuals with Cockayne Syndrome
View in own window
| System/Concern | Evaluation | Frequency |
|---|
|
Diet
| Dietary assessment | 2x/yr |
|
Nervous system
| Clinical review |
|
Eye
| Ophthalmologic assessment (eval for cataracts & retinopathy) | 2x/yr until age 4 yrs, then annually |
|
Hearing
| Hearing assessment | Annually |
|
Diabetes
| Blood glucose |
|
Liver
| Liver enzymes |
|
Kidney
| Kidney function; uric acid & proteinuria |
|
Cardiovascular
| Blood pressure |
Agents/Circumstances to Avoid
Excessive sun exposure should be avoided.
Use of metronidazole should be avoided in any circumstance (risk of severe hepatitis) [Wilson et al 2015].
Extra vigilance is needed for opioid and sedative use due to exaggerated response to these types of medications [Wilson et al 2016].
Growth hormone (GH) levels in individuals with Cockayne syndrome (CS) may be elevated or decreased [Park et al 1994, Hamamy et al 2005]. While individuals with CS do not appear to be at increased risk for malignancy (an effect which may be due to simultaneous transcription and cell proliferation deficiency), it is theoretically possible that GH treatment could reverse this compensatory effect and promote tumor growth. Therefore, in the absence of safety and efficacy data, GH treatment cannot be recommended in individuals with CS.
Pregnancy Management
No individuals with classic or severe CS (types I or II) have been known to reproduce. A successful (but very difficult) pregnancy has been reported in a young woman with mild CS (type III) [Lahiri & Davies 2003].
In pregnant women with CS, the limited size of the pelvis and abdomen is the major obstacle to the growth of the fetus and the major threat to pregnancy outcome. Prevention of premature labor and cesarean section under spinal anesthesia are usually needed [Lahiri & Davies 2003, Rawlinson & Webster 2003].
Therapies Under Investigation
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Genetic Counseling
Genetic counseling is the process of providing individuals and families with
information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members; it is not meant to address all personal, cultural, or
ethical issues that may arise or to substitute for consultation with a genetics
professional. —ED.
Carrier Detection
Carrier testing for at-risk relatives requires prior identification of the ERCC6 or ERCC8 pathogenic variants in the family.
Prenatal Testing and Preimplantation Genetic Testing
Once the CS-causing pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible.
Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.
Resources
GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click here.
Amy and Friends
United Kingdom
Email: info@amyandfriends.org
Amy and Friends
Netherlands
Cockayne Syndrome Network
Phone: 703-727-0404; 865-466-4634
Email: cockaynesyndrome@gmail.com
L’Association Les P’tits Bouts
France
Phone: 06 81 82 28 03
MedlinePlus
NCBI Genes and Disease
Xeroderma Pigmentosum Society, Inc (XP Society)
XP Society has material on their site related to UV protection/avoidance.
Phone: 877-XPS-CURE (877-977-2873); 518-851-2612
Email: xps@xps.org
GenIDA (Genetically determined Intellectual Disabilities and Autism Spectrum Disorders) Registry
A website for patients, families, and professionals; GenIDA hosts a specific registry for Cockayne syndrome.
Email: genida@igbmc.fr
Myelin Disorders Bioregistry Project
Phone: 215-590-1719
Email: sherbinio@chop.edu
Molecular Genetics
Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.
Table A.
Cockayne Syndrome: Genes and Databases
View in own window
Data are compiled from the following standard references: gene from
HGNC;
chromosome locus from
OMIM;
protein from UniProt.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
here.
Table B.
View in own window
|
133540 | COCKAYNE SYNDROME B; CSB |
|
216400 | COCKAYNE SYNDROME A; CSA |
|
609412 | ERCC EXCISION REPAIR 8, CSA UBIQUITIN LIGASE COMPLEX SUBUNIT; ERCC8 |
|
609413 | ERCC EXCISION REPAIR 6, CHROMATIN REMODELING FACTOR; ERCC6 |
Molecular Pathogenesis
The proteins encoded by ERCC6 and ERCC8 both play important roles in transcription-coupled nucleotide excision repair (TC-NER), a DNA repair process that preferentially removes UV-induced pyrimidine dimers and other transcription-blocking lesions from the transcribed strands of active genes.
ERCC6 encodes DNA excision repair protein ERCC-6, which has at least seven domains that are conserved in DNA and RNA helicases. This protein appears to enhance the elongation of transcription products by RNA polymerase II, and possibly also RNA polymerases I and III.
ERCC8 encodes DNA excision repair protein ERCC-8, which is a WD-repeat (tryptophan aspartate-repeats) protein component of a large cullin4-mediated E3-ubiquitin ligase complex.
A deficiency of TC-NER is sufficient to explain the cutaneous photosensitivity of individuals with CS. It is unlikely, however, to explain the growth failure and neurodegeneration that typify CS. In contrast to CS, most individuals with xeroderma pigmentosum (XP) have normal growth and neurologic function, despite having combined deficiencies of both TC-NER and "global genome nucleotide excision repair" (GG-NER). To explain this apparent paradox, it has been suggested that CS proteins have other functions including roles in transcription reinitiation after genotoxic stress [Epanchintsev et al 2017], repair of oxidative DNA damage [Nardo et al 2009, Ranes et al 2016], and mitochondrial metabolism [Kamenisch & Berneburg 2013, Chatre et al 2015, Scheibye-Knudsen et al 2016].
Mechanism of disease causation. CS occurs through a loss-of-function mechanism.
Table 7.
Laboratory Technical Considerations for Genes Causing Cockayne Syndrome
View in own window
- 1.
Genes in alphabetic order
Table 8.
Notable Pathogenic Variants in Genes Causing Cockayne Syndrome
View in own window
Variants listed in the table have been provided by the author. GeneReviews staff have not independently verified the classification of variants.
GeneReviews follows the standard naming conventions of the Human Genome Variation Society (varnomen.hgvs.org). See Quick Reference for an explanation of nomenclature.
- 1.
Genes in alphabetic order
References
Literature Cited
Baez S, Couto B, Herrera E, Bocanegra Y, Trujillo-Orrego N, Madrigal-Zapata L, Cardona JF, Manes F, Ibanez A, Villegas A. Tracking the cognitive, social, and neuroanatomical profile in early neurodegeneration: Type III Cockayne syndrome.
Front Aging Neurosci. 2013;5:80. [
PMC free article: PMC3840614] [
PubMed: 24324434]
Bloch-Zupan A, Rousseaux M, Laugel-Haushalter V, Schmittbuhl M, Mathis R, Desforges E, Koob M, Zaloszyc A, Dollfus H, Laugel V. A possible cranio-oro-facial phenotype in Cockayne syndrome.
Orphanet J Rare Dis. 2013;8:9. [
PMC free article: PMC3599377] [
PubMed: 23311583]
Calmels N, Botta E, Jia N, Fawcett H, Nardo T, Nakazawa Y, Lanzafame M, Moriwaki S, Sugita K, Kubota M, Obringer C, Spitz MA, Stefanini M, Laugel V, Orioli D, Ogi T, Lehmann A. Functional and clinical relevance of novel mutations in a large cohort of patients with Cockayne syndrome.
J Med Genet. 2018;55:329–43. [
PubMed: 29572252]
Chatre L, Biard DS, Sarasin A, Ricchetti M. Reversal of mitochondrial defects with CSB-dependent serine protease inhibitors in patient cells of the progeroid Cockayne syndrome.
Proc Natl Acad Sci U S A. 2015;112:E2910–9. [
PMC free article: PMC4460464] [
PubMed: 26038566]
Chebly A, Corbani S, Abou Ghoch J, Mehawej C, Megarbane A, Chouery E. First molecular study in Lebanese patients with Cockayne syndrome and report of a novel mutation in ERCC8 gene.
BMC Med Genet. 2018;19:161. [
PMC free article: PMC6131905] [
PubMed: 30200888]
Epanchintsev A, Costanzo F, Rauschendorf MA, Caputo M, Ye T, Donnio LM, Proietti-de-Santis L, Coin F, Laugel V, Egly JM. Cockayne's Syndrome A and B Proteins Regulate Transcription Arrest after Genotoxic Stress by Promoting ATF3 Degradation.
Mol Cell. 2017;68:1054–66.e6. [
PubMed: 29225035]
Frouin E, Laugel V, Durand M, Dollfus H, Lipsker D. Dermatologic findings in 16 patients with Cockayne syndrome and cerebro-oculo-facial-skeletal syndrome.
JAMA Dermatol. 2013;149:1414–8. [
PubMed: 24154677]
Graham JM Jr, Hennekam R, Dobyns WB, Roeder E, Busch D. MICRO syndrome: an entity distinct from COFS syndrome.
Am J Med Genet A. 2004;128A:235–45. [
PubMed: 15216543]
Hamamy HA, Daas HA, Shegem NS, Al-Hadidy AM, Ajlouni K. Cockayne syndrome in 2 siblings.
Saudi Med J. 2005;26:875–9. [
PubMed: 15951889]
Hayashi M, Miwa-Saito N, Tanuma N, Kubota M. Brain vascular changes in Cockayne syndrome.
Neuropathology. 2012;32:113–7. [
PubMed: 21749465]
Horibata K, Iwamoto Y, Kuraoka I, Jaspers NG, Kurimasa A, Oshimura M, Ichihashi M, Tanaka K. Complete absence of Cockayne syndrome group B gene product gives rise to UV-sensitive syndrome but not Cockayne syndrome.
Proc Natl Acad Sci U S A. 2004;101:15410–5. [
PMC free article: PMC524447] [
PubMed: 15486090]
Jaakkola E, Mustonen A, Olsen P, Miettinen S, Savuoja T, Raams A, Jaspers NG, Shao H, Wu BL, Ignatius J. ERCC6 founder mutation identified in Finnish patients with COFS syndrome.
Clin Genet. 2010;78:541–7. [
PubMed: 20456449]
Kamenisch Y, Berneburg M. Mitochondrial CSA and CSB: protein interactions and protection from ageing associated DNA mutations.
Mech Ageing Dev. 2013;134:270–4. [
PubMed: 23562423]
Khayat M, Hardouf H, Zlotogora J, Shalev SA. High carriers frequency of an apparently ancient founder mutation p.Tyr322X in the ERCC8 gene responsible for Cockayne syndrome among Christian Arabs in Northern Israel.
Am J Med Genet A. 2010;152A:3091–4. [
PubMed: 21108394]
Kleijer WJ, Laugel V, Berneburg M, Nardo T, Fawcett H, Gratchev A, Jaspers NG, Sarasin A, Stefanini M, Lehmann AR. Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy.
DNA Repair (Amst). 2008;7:744–50. [
PubMed: 18329345]
Koob M, Laugel V, Durand M, Fothergill H, Dalloz C, Sauvanaud F, Dollfus H, Namer IJ, Dietemann JL. Neuroimaging in Cockayne syndrome.
AJNR Am J Neuroradiol. 2010;31:1623–30. [
PMC free article: PMC7964976] [
PubMed: 20522568]
Koob M, Rousseau F, Laugel V, Meyer N, Armspach JP, Girard N, Dietemann JL. Cockayne syndrome: a diffusion tensor imaging and volumetric study.
Br J Radiol. 2016;89:20151033. [
PMC free article: PMC5124826] [
PubMed: 27643390]
Lahiri S, Davies N. Cockayne's Syndrome: case report of a successful pregnancy.
BJOG. 2003;110:871–2. [
PubMed: 14511973]
Laugel V. Cockayne syndrome: the expanding clinical and mutational spectrum.
Mech Ageing Dev. 2013;134:161–70. [
PubMed: 23428416]
Laugel V, Dalloz C, Durand M, Sauvanaud F, Kristensen U, Vincent MC, Pasquier L, Odent S, Cormier-Daire V, Gener B, Tobias ES, Tolmie JL, Martin-Coignard D, Drouin-Garraud V, Heron D, Journel H, Raffo E, Vigneron J, Lyonnet S, Murday V, Gubser-Mercati D, Funalot B, Brueton L, Sanchez Del Pozo J, Muñoz E, Gennery AR, Salih M, Noruzinia M, Prescott K, Ramos L, Stark Z, Fieggen K, Chabrol B, Sarda P, Edery P, Bloch-Zupan A, Fawcett H, Pham D, Egly JM, Lehmann AR, Sarasin A, Dollfus H. Mutation update for the CSB/ERCC6 and CSA/ERCC8 genes involved in Cockayne syndrome.
Hum Mutat. 2010;31:113–26. [
PubMed: 19894250]
Laugel V, Dalloz C, Tobias ES, Tolmie JL, Martin-Coignard D, Drouin-Garraud V, Valayannopoulos V, Sarasin A, Dollfus H. Cerebro-oculo-facio-skeletal syndrome: three additional cases with CSB mutations, new diagnostic criteria and an approach to investigation.
J Med Genet. 2008;45:564–71. [
PubMed: 18628313]
Nakazawa Y, Yamashita S, Lehmann AR, Ogi T. A semi-automated non-radioactive system for measuring recovery of RNA synthesis and unscheduled DNA synthesis using ethynyluracil derivatives.
DNA Repair (Amst). 2010;9:506–16. [
PubMed: 20171149]
Nance MA, Berry SA. Cockayne syndrome: review of 140 cases.
Am J Med Genet. 1992;42:68–84. [
PubMed: 1308368]
Nardo T, Oneda R, Spivak G, Vaz B, Mortier L, Thomas P, Orioli D, Laugel V, Stary A, Hanawalt PC, Sarasin A, Stefanini M. A UV-sensitive syndrome patient with a specific CSA mutation reveals separable roles for CSA in response to UV and oxidative DNA damage.
Proc Natl Acad Sci U S A. 2009;106:6209–14. [
PMC free article: PMC2667150] [
PubMed: 19329487]
Natale V. A comprehensive description of the severity groups in Cockayne syndrome.
Am J Med Genet A. 2011;155A:1081–95. [
PubMed: 21480477]
Neilan EG, Delgado MR, Donovan MA, Kim SY, Jou RL, Wu BL, Kang PB. Response of motor complications in Cockayne syndrome to carbidopa-levodopa.
Arch Neurol. 2008;65:1117–21. [
PubMed: 18695064]
Pena SD, Shokeir MH. Autosomal recessive cerebro-oculo-facio-skeletal (COFS) syndrome.
Clin Genet. 1974;5:285–93. [
PubMed: 4211825]
Qin Y, Guo T, Li G, Tang TS, Zhao S, Jiao X, Gong J, Gao F, Guo C, Simpson JL, Chen ZJ. CSB-PGBD3 Mutations Cause Premature Ovarian Failure.
PLoS Genet. 2015;11:e1005419. [
PMC free article: PMC4517778] [
PubMed: 26218421]
Ranes M, Boeing S, Wang Y, Wienholz F, Menoni H, Walker J, Encheva V, Chakravarty P, Mari PO, Stewart A, Giglia-Mari G, Snijders AP, Vermeulen W, Svejstrup JQ. A ubiquitylation site in Cockayne syndrome B required for repair of oxidative DNA damage, but not for transcription-coupled nucleotide excision repair.
Nucleic Acids Res. 2016;44:5246–55. [
PMC free article: PMC4914099] [
PubMed: 27060134]
Rawlinson SC, Webster VJ. Spinal anaesthesia for caesarean section in a patient with Cockayne syndrome.
Int J Obstet Anesth. 2003;12:297–9. [
PubMed: 15321464]
Scheibye-Knudsen M, Tseng A, Borch Jensen M, Scheibye-Alsing K, Fang EF, Iyama T, Bharti SK, Marosi K, Froetscher L, Kassahun H, Eckley DM, Maul RW, Bastian P, De S, Ghosh S, Nilsen H, Goldberg IG, Mattson MP, Wilson DM 3rd, Brosh RM Jr, Gorospe M, Bohr VA. Cockayne syndrome group A and B proteins converge on transcription-linked resolution of non-B DNA.
Proc Natl Acad Sci U S A. 2016;113:12502–7. [
PMC free article: PMC5098674] [
PubMed: 27791127]
Stern-Delfils A, Spitz MA, Durand M, Obringer C, Calmels N, Olagne J, Pillay K, Fieggen K, Laugel V, Zaloszyc A. Renal disease in Cockayne syndrome.
Eur J Med Genet. 2020;63:103612. [
PubMed: 30630117]
Van Wyhe RD, Emery CV, Williamson RA. Cochlear implantation in pediatric patients with Cockayne Syndrome.
Int J Pediatr Otorhinolaryngol. 2018;106:64–67. [
PubMed: 29447894]
Weidenheim KM, Dickson DW, Rapin I. Neuropathology of Cockayne syndrome: Evidence for impaired development, premature aging, and neurodegeneration.
Mech Ageing Dev. 2009;130:619–36. [
PubMed: 19647012]
Wilson BT, Stark Z, Sutton RE, Danda S, Ekbote AV, Elsayed SM, Gibson L, Goodship JA, Jackson AP, Keng WT, King MD, McCann E, Motojima T, Murray JE, Omata T, Pilz D, Pope K, Sugita K, White SM, Wilson IJ. The Cockayne Syndrome Natural History (CoSyNH) study: clinical findings in 102 individuals and recommendations for care.
Genet Med. 2016;18:483–93. [
PMC free article: PMC4857186] [
PubMed: 26204423]
Wilson BT, Strong A, O'Kelly S, Munkley J, Stark Z. Metronidazole toxicity in Cockayne syndrome: a case series.
Pediatrics. 2015;136:e706–8. [
PubMed: 26304821]
Chapter Notes
Author History
Vincent Laugel, MD, PhD (2012-present)
Martha A Nance, MD; Park Nicollet Clinic (2000-2006)
Edward G Neilan, MD, PhD; Children's Hospital Boston (2006-2012)
Revision History
29 August 2019 (ha) Comprehensive update posted live
14 June 2012 (me) Comprehensive update posted live
7 March 2006 (me) Comprehensive update posted live
24 September 2003 (cd) Revision: clinical test no longer available
21 August 2003 (cd) Revision: change in
gene name
31 July 2003 (me) Comprehensive update posted live
15 October 2001 (mn) Author revision
28 December 2000 (me) Review posted live
June 2000 (mn) Original submission
